Report LibraryAll Reports
Datamonitor Healthcare Infectious Diseases Disease Analysis: Hepatitis C
October 08, 2021
Since peaking in 2015, the sales value of the hepatitis C market has entered a protracted decline as intensifying competition has slashed treatment costs, and patient numbers have fallen sharply in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK). Despite significant improvements in patient access to treatment as payers have lifted treatment restrictions in response to lower treatment costs, the patient pool is expected to continue to shrink as the influx of newly diagnosed patients fails to offset the high number of patients exiting the treatment algorithm due to cure. Thus, investment in initiatives to improve screening uptake and linkage to care will be critical in softening the pace of this decline.
The current treatment paradigm is dominated by two competing pan-genotypic regimens, Epclusa and Mavyret, which possess excellent efficacy (cure rates of ≥95%), strong tolerability profiles (≤1% of patients discontinue due to adverse events), and convenient once-daily dosing schedules with treatment durations of 8–12 weeks.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Hepatitis C (HCV) (Antiviral)|